MedPath

Berberis Vulgaris Consumption and Blood Pressure

Not Applicable
Completed
Conditions
Blood Pressure
Lipid Profile
Cardiovascular Risk Factor
Interventions
Dietary Supplement: berberis vulgaris=barberry
Dietary Supplement: Placebo
Registration Number
NCT04084847
Lead Sponsor
Shahid Beheshti University
Brief Summary

The aim of this study is to investigate the effect of barberry consumption on systolic and diastolic blood pressure, serum lipids, and inflammatory status. The study will involve cases having elevated BP (129/ \< 85) and known hypertensive patients on medical treatment. Seventy people will be randomized into two groups, including intervention (barberry) or placebo groups.

Before and after of 8 week intervention, 24-hour ambulatory blood pressure monitoring will be done and fasting venous blood sample will be taken to measure plasma lipids. In addition, 24-hour urine will be collected to measure its sodium content and estimate sodium intake.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
78
Inclusion Criteria
  • willingness to participate in the study
  • age between 20-65 years
  • having elevated BP (129/ < 85) and known hypertensive patients on medical treatment
  • at least one other classical cardiovascular disease risk factors, including hyperlipidemia or diabetes mellitus
Exclusion Criteria
  • Unwillingness to continue participation
  • BMI> 30
  • patients on nitrates
  • high doses of statins consumption (Atorvastatin>40 mg/day or Rosuvastatin>20 mg/day)
  • consumption of vitamins or minerals supplements during past month
  • Chronic kidney disease stage 4 or 5

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Barberryberberis vulgaris=barberryDaily consumption of barberry in powder form.
placeboPlaceboDaily consumption of placebo powder.
Primary Outcome Measures
NameTimeMethod
blood pressureat 8 weeks

mean of systolic and diastolic blood pressure of participants measured by ambulatory 24 hour blood pressure monitoring

Secondary Outcome Measures
NameTimeMethod
lipid profileat 8 weeks

plasma TC, LDL-C, HDL-C, TG

plasma NOxat 8 weeks

concentration of nitrite and nitrate in plasma

Inflammatory cytokineat 8 weeks

Plasma Interleukin-6

Trial Locations

Locations (1)

Rajaei Cardiovascular, Medical & Research Center

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath